About
Our Story
Our People
Careers
Science
Our Science
Pipeline
Izokibep
Lonigutamab
XLRN-517
Community
Patients
Partnerships
Investors
For Investors
Press Releases
Events
News Center
News Center
Media Kit
Contact

News Center

AllCompany NewsPress ReleasesEventsResources

Presentations

Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
Presentation
Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
View PresentationArrow purple
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits
Presentation
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits
View PresentationArrow purple

An innovative biopharma company that identifies, acquires and accelerates the development and commercialization of transformative medicines.

Get company updates to your inbox
About us
Our Story Our People Careers News Center
Science
Our Science Pipeline Izokibep Lonigutamab XLRN-517
Community
Investors Patients Partnerships
Contact
info@acelyrin.com Contact Us Media Kit
Gradient

©2023 ACELYRIN, INC. All Rights Reserved. | ACELYRIN and the ACELYRIN logo are trademarks of ACELYRIN, INC.

Acelyrin Linkedin
Privacy Policy | Terms